I. AMENDMENTS

IN THE CLAIMS

Cancel claims 22, 23, 29, and 30 without prejudice to renewal.

Please enter the amendments to claims 21, 24, 26, and 28, as shown below.

Please enter new claims 31-35, as shown below.

1.-20. (Canceled)

21. (Currently Amended) A cationic liposome comprising a cationic lipid and a detectable label~~, wherein the cationic liposome has a diameter of about 20 to 200 nm~~, wherein said cationic liposome has a zeta potential greater than 0 mV, and wherein said cationic liposome has greater affinity for angiogenic endothelial cells compared to corresponding normal endothelial cells.

22.-23 (Canceled)

24. (Currently Amended) The cationic liposome of claim 21, wherein the detectable label is selected from ~~the group consisting of~~ a fluorescent label ~~labels~~, a histochemical label ~~labels~~, an immunochemical label ~~labels~~, and a radioactive label ~~labels~~.

25. (Original) A pharmaceutical composition comprising the cationic liposome of claim 21 and a pharmaceutically acceptable carrier.

26. (Currently Amended) A cationic liposomal composition for *in vivo* diagnostic use comprising a cationic lipid and a detectable label~~, wherein the cationic liposome has a diameter of about 20 to 200 nm~~, wherein said cationic liposome has a zeta potential greater than 0 mV, wherein said cationic liposome has greater affinity for angiogenic endothelial cells compared to corresponding normal endothelial cells, and wherein the liposomal composition is formulated for systemic delivery.

27. (Original) The cationic liposomal composition of claim 26, wherein the composition is formulated for injection into the circulatory system.

28. (Currently Amended) A cationic liposome consisting essentially of a cationic lipid and a detectable label~~, wherein the cationic liposome has a diameter of about 20 to 200 nm~~, wherein said cationic liposome has a zeta potential greater than 0 mV, and wherein said cationic liposome has greater affinity for angiogenic endothelial cells compared to corresponding normal endothelial cells.

29.-30. (Canceled)

-- 31. (New) A method for selectively labeling angiogenic endothelial cells *in vivo*, the method comprising administering to a mammal a liposomal complex comprising cationic lipids and a detectable label wherein the complex has greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells;

and allowing the liposomal complex to selectively associate with angiogenic endothelial cells of an angiogenic blood vessel for a time and in a manner such that the angiogenic endothelial cells are detectably labeled.

32. (New) The method of claim 31, wherein the liposomal composition is administered by injection into the circulatory system of the mammal, and further wherein the liposomal composition has a five-fold or greater affinity for angiogenic endothelial cells as compared to corresponding normal endothelial cells.

33. (New) The method of claim 31, wherein the detectable label is selected from a fluorescent label, a histochemical label, an immunohistochemical label, and a radioactive label. --

34. (New) The method of claim 31, wherein the cationic liposome has a zeta potential greater than 0 mV.

35. (New) The cationic liposome of claim 21, wherein the cationic liposome comprises about 5 mole % or more cationic lipid. --